drugset / Trial / NCT03017326

Summary

The PHITT trial is an over-arching study for patients with Hepatoblastoma (HB) and Hepatocellular Carcinoma (HCC). This trial will use a risk-adapted approach to the treatment of children diagnosed with HB. Children with HCC will be included as a separate cohort.

Timeline

Start
2017-08-24
Primary completion
2026-12-31
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 500 mg/m2
Comparator Carboplatin Small molecule 800 mg/m2
Subject Cisplatin Other / unclassified 70 mg/m2
Subject Cisplatin Other / unclassified 80 mg/m2
Subject Cisplatin Other / unclassified 100 mg/m2
Subject Doxorubicin Other / unclassified 30 mg/m2
Subject Doxorubicin Other / unclassified 40 mg/m2
Subject Doxorubicin Other / unclassified 60 mg/m2
Comparator Etoposide Small molecule 400 mg/m2
Comparator Gemcitabine Small molecule 1000 mg/m2
Comparator Irinotecan Small molecule 250 mg/m2
Comparator Oxaliplatin Small molecule 100 mg/m2
Comparator Sorafenib Small molecule 300 mg/m2
Comparator Vincristine Small molecule 3 mg/m2
Comparator Vincristine Small molecule 4.5 mg/m2
Comparator fluorouracil Small molecule 600 mg/m2

Indications